학술논문

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study
Document Type
Article
Source
In: The Lancet. (The Lancet, 10 December 2011, 378(9808):2005-2012)
Subject
Language
English
ISSN
01406736
1474547X